Drugs / CUREAⓇ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06574750 | Oct 2021 → May 2023 | — | Seoul National University Bundang Hospital | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CUREAⓇ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06574750 ↗ |
| Known as | Curea | “This study aimed to evaluate the efficacy and safety of a new monophasic HA filler, Curea, for NLF correction compared with the widely used Juvéderm.” PMID 40707029 ↗ Jul 2025 |
| Modality | Other / unclassified | “a new monophasic HA filler, Curea, for NLF correction” PMID 40707029 ↗ Jul 2025 |